AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03641768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.
Study NCT03641768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET
Description: You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.
Study NCT03641768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Florbetapir
Description: At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
Study NCT02622581 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
Study NCT03441971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE PV1
Description: Implantation of GORE PV1 Device for procedure to replace the pulmonary valve and reconstruct the right ventricular outflow tract (RVOT).
Study NCT04409457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fasting state
Description: 16 hours of fasting
Study NCT04409457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fed state
Description: fed a standardized meal
Study NCT04409457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging
Description: neuroimaging with computational modeling
Study NCT01750242 — intervention group
Intervention type: DEVICE
Intervention: Medtronic DBS system
Description: Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
Study NCT02209389 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
Study NCT03628560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct Step-Wise Normocapnia desaturation sequence
Description: Blood carbon dioxide controlled at normal value (normocapnia).
Study NCT03628560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct Slope Normocapnia desaturation sequence
Description: Blood carbon dioxide controlled at normal value (normocapnia).
Study NCT03628560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct Step-Wise Hypocapnia desaturation sequence
Description: Blood carbon dioxide controlled at lower than normal value (hypocapnia).
Study NCT03628560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct Slope Hypocapnia desaturation sequence
Description: Blood carbon dioxide controlled at lower than normal value (hypocapnia).
Study NCT02702869 — intervention group
Intervention type: PROCEDURE
Intervention: cleft lip repair
Study NCT02702869 — intervention group
Intervention type: PROCEDURE
Intervention: cleft palate repair
Study NCT02702869 — intervention group
Intervention type: PROCEDURE
Intervention: oronasal fistula repair
Study NCT02702869 — intervention group
Intervention type: PROCEDURE
Intervention: pharyngoplasty
Study NCT02702869 — intervention group
Intervention type: PROCEDURE
Intervention: gingivoperiosteoplasty
Study NCT02702869 — intervention group
Intervention type: PROCEDURE
Intervention: LeFort-1 maxillary repositioning
Study NCT03641768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radioligand 18F-AV-1451
Description: At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
Study NCT00664339 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flu Vaccine
Description: Single dose of Flu vaccine by year (1)
Study NCT00664339 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional medical therapy for heart failure
Description: According with the international guidelines
Study NCT05319899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
Study NCT05319899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
Study NCT03481166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education on breastfeeding pain
Description: A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.
Study NCT01557777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: QD
Study NCT03536780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab and Gemcitabine
Description: * Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~* Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle
Study NCT02350413 — intervention group
Intervention type: OTHER
Intervention: The Endometriosis Health Profile EPH-30
Description: Self-reported questionnaires
Study NCT04463693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant
Description: Insertion of the contraceptive implant at an alternative insertion site located over the scapula
Study NCT01747408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Albumin
Description: 25% human albumin given in four escalating doses:~1. Group 1: .625g/kg infused over 3hrs daily X 7day~2. Group 2: 1.25g/kg infused over 3hrs daily X 7day~3. Group 3: 1.875g/kg infused over 3hrs daily X 7day~4. Group 4: 2.5g/kg infused over 3hrs daily X 7day
Study NCT00559429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 50mg/m2 IV on day 1 and day 22
Study NCT00559429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV on day 1 and day 22
Study NCT00559429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
Study NCT04467229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus group
Description: 5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.
Study NCT00503581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT00503581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy
Study NCT00853255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Description: Vaccine administered by nasal spray
Study NCT03628560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROBD Step-Wise desaturation sequence
Description: Blood carbon dioxide is controlled at normal or lower value by subject's own breathing rate.
Study NCT02702869 — intervention group
Intervention type: PROCEDURE
Intervention: rhinoplasty
Study NCT02551224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient preference questionnaire
Description: The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
Study NCT02702869 — intervention group
Intervention type: PROCEDURE
Intervention: myringotomy and tympanostomy tube placement
Study NCT02702869 — intervention group
Intervention type: OTHER
Intervention: speech therapy
Study NCT02702869 — intervention group
Intervention type: PROCEDURE
Intervention: orthodontia
Study NCT02702869 — intervention group
Intervention type: PROCEDURE
Intervention: presurgical orthopedics
Study NCT02702869 — intervention group
Intervention type: DEVICE
Intervention: sound amplification for hearing
Study NCT00503581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00503581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00503581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: given orally
Study NCT00503581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00503581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00503581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00503581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00503581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: undergo hysterectomy
Study NCT00503581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: undergo hysterectomy
Study NCT01364558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
Study NCT04134468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvorhyaluronidase alfa
Description: IV infusion
Study NCT04134468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: IV infusion
Study NCT04134468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion
Study NCT02117648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT02117648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Administered orally
Study NCT02637752 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling or nutrition/physical counselling
Description: A brief (5-10 minute) counseling session for caregivers of the intervention group aimed to encourage an increase in the child's physical activity and decrease sugar-sweetened beverage consumption and screen time. Additionally, the caregivers of the intervention group were provided with the following handouts: five steps to a healthy body weight for teens; beverages; physical activity tips for children 5-11 years; Canadian physical activity guidelines for children 5-11; and Canadian sedentary behavior guidelines for children 5-11.
Study NCT03931408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate
Description: Gentamicin will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
Study NCT01364558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
Study NCT03931408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo instillation (saline alone)
Description: Saline will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
Study NCT03931408 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No instillation
Description: Participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
Study NCT03516591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMV564 14-Day CIV
Description: A 14-Day Continuous Intravenous Infusion regimen
Study NCT01813591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
Study NCT02600702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Siriraj knee exercise
Description: Siriraj knee exercise, 12 position of exercise protocol
Study NCT02600702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Siriraj knee exercise
Description: Siriraj knee exercise, 12 position of exercise protocol
Study NCT02600702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical modalities
Study NCT04173078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Distress Intolerance Intervention
Study NCT04173078 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized Healthy Behaviors Intervention
Study NCT00002602 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-CRT
Description: 3 dimensional conformal radiation therapy
Study NCT00686660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycling, walking
Description: In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years.
Study NCT00686660 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cycling, non-walking
Description: In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't receive walk training.
Study NCT00686660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking, walking
Description: In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years.
Study NCT00686660 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: walking, non-walking
Description: In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't walking at community.
Study NCT01364558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
Study NCT03656328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri 4659
Description: supplementation with L. reuteri 4659 twice a day for 10 days during the standard antibiotic therapy
Study NCT03656328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: supplementation with a Placebo capsule twice a day for 10 days during the standard antibiotic therapy
Study NCT01887873 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hyaluronan Thiomer i.o. implant
Study NCT02608710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 4.5 mg
Study NCT02608710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 6 mg
Study NCT04876066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Weight-based ketamine dose will be prepared and delivered personally to study physician or study personnel by pharmacy personnel as is done during standard protocol for use of ketamine not part of a clinical study.
Study NCT03124472 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine artery ligation
Description: Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged
Study NCT03124472 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower segment Cesarean section
Description: Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.~* Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.~* Closure of the anterior abdominal wall in layers
Study NCT04183127 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: ACPs, qualified or in training, will be invited to participate by email. Interested participants will be provided with study materials and asked to complete an online eligibility questionnaire; if eligible, contact details will also be recorded. Participants will be invited to take part in a focus group about their experience in developing clinical competence and their opinions on role identity. Data collection will consist of focus groups.
Study NCT02608710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 12 mg
Study NCT01896531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
Study NCT01896531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
Study NCT01896531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
Study NCT02714426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain health
Description: Eight weekly group brain health sessions lasting 90-120 minutes. The intervention is psychoeducational, and each week presents information from NIH regarding factors that may promote cognitive health in late life (e.g., sleep, physical activity, social engagement and leisure, cognitive training). Weekly sessions are supplemented with educational videos and group discussion. Weekly homework consists of readings about brain health.
Study NCT02529215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-in-time training (JITT)
Description: The JITT training is a 20 minute simulation-based teaching session targeting: (1) CPR quality and (2) medication administration.
Study NCT00603837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoWrap
Description: This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.